NIKKEI 225
36,818.81 -1,260.89 (-3.31%) HANG SENG
16,091.59 -294.28 (-1.80%) CRUDE OIL
85.92 +3.19 (+3.86%) GOLD FUTURES
2,418.90 +20.90 (+0.87%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,457.73 -391.61 (-0.79%)
Xeris Pharmaceuticals, Inc. (XERS)
After hours:
| Previous close | 1.7800 |
| Open | 1.8000 |
| Bid | 1.7500 x 800 |
| Ask | 1.7800 x 400 |
| Day's range | 1.7300 - 1.8000 |
| 52-week range | 1.4600 - 3.2600 |
| Volume | |
| Avg. volume | 1,904,422 |
| Market cap | 247.197M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO, April 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.
- Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CHICAGO, April 02, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit "Events" on
- Business Wire
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
CHICAGO, March 06, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events.
